4/A: Milestone COO Nelson Amends Stock Option Filing
Executive Compensation Update
Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, filed an amended Form 4 to correct the exercise price of 204,000 employee stock options.
Summary
- An amendment to a previously filed Form 4 was submitted by Jeffrey Edward Nelson, Chief Operating Officer of Milestone Pharmaceuticals Inc.
- The amendment corrects the exercise price of 204,000 employee stock options, which was previously stated incorrectly.
- The corrected exercise price for the employee stock options is $1.96.
- The options were granted on February 2, 2026, and are set to expire on February 2, 2036.
- The vesting schedule for these options dictates that one-fourth (1/4th) of the shares vest on February 2, 2027, with one thirty-sixth (1/36th) of the remaining shares vesting each month thereafter, subject to continuous service by the Reporting Person.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is an administrative correction of an executive's stock option details and does not impact the company's operational or financial performance.
Industry Context
StockSavvy.ai notes that Form 4/A filings are routine administrative corrections and typically do not reflect significant operational or strategic shifts within the pharmaceutical industry.
Stakeholder Impact
- Shareholders: Provides clarity and accuracy regarding executive compensation details, specifically the exercise price of stock options.
Key Dates
| Date | Description |
|---|---|
| 02/02/2026 | Date of earliest transaction (acquisition of employee stock options). |
| 02/04/2026 | Date of original Form 4 filing. |
| 02/05/2026 | Date of this amended Form 4/A filing. |
| 02/02/2027 | First vesting date for one-fourth of the employee stock options. |
| 02/02/2036 | Expiration date of the employee stock options. |
Recommendation
holdThis filing is an administrative correction of an executive's stock option exercise price and does not provide new information that would warrant a change in investment recommendation for Milestone Pharmaceuticals Inc.
Keywords
Milestone Pharmaceuticals, MIST, Jeffrey Edward Nelson, Form 4/A, SEC filing, stock options, beneficial ownership, executive compensation, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.